A miRNA signature for defining aggressive phenotype and prognosis in gliomas

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Barbano, Raffaela ^a   Palumbo, Orazio ^a   Pasculli, Barbara ^b   Galasso, Marco ^c   Volinia, Stefano ^c   D'Angelo, Vincenzo ^a   Icolaro, Nadia ^a   Coco, Michelina ^a   Dimitri, Lucia ^a   Graziano, Paolo ^a   Copetti, Massimiliano ^a   Valori, Vanna Maria ^a   Maiello, Evaristo ^a   Carella, Massimo ^a   Fazio, Vito Michele ^a,d   Parrella, Paola ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 21; MICRORNA 210; MICRORNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; PHENOTYPE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; BRAIN TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; PHENOTYPE; PROGNOSIS;

EID: 84941196163     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108950     Document Type: Article

References (21)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
2. Galasso M, Sandhu SK, Volinia S (2012) MicroRNA expression signatures in solid malignancies. Cancer J 18: 238-243.
3. Parrella P, la Torre A, Copetti M, Valori VM, Barbano R, et al. (2009) High specificity of quantitative methylation-specific PCR analysis for MGMT promoter hypermethylation detection in gliomas. J Biomed Biotechnol 2009:531692 doi:10.1155/2009/531692. Epub 2009 Jun 1.
4. Parrella P, Barbano R, Pasculli B, Fontana A, Copetti M, et al. (2014) Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. Mol Cancer 13: 142.
5. Kim TM, Huang W, Park R, Park PJ, Johnson MD (2011) A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 71: 3387-3399.
6. Meier P, Kaplan E (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 158: 457-481.
7. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5 year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 59-466.
8. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007.
9. Weller M, Wick W, von Deimling A (2011) Isocitrate Deydrogenase mutations: a challenge to traditional views on the genesis and malignant progression in gliomas. Glia 59:1200-1204.
10. Muscarella LA, Barbano R, D'Angelo V, Copetti M, Coco M, et al. (2011) Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. Epigenetics 6: 317-325.
11. Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, et al. (2011) MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS One 6:e20600. doi: 10.1371/journal.pone.0020600.
12. Rong Y, Durden DL, Van Meir EG, Brat DJ (2006) 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65: 529-539.
13. Bao B, Azmi AS, Ali S, Ahmad A, Li Y, et al. (2012) The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumour aggressiveness. Biochim Biophys Acta 1826: 272-296.
14. Bao B, Ahmad A, Kong D, Ali S, Azmi AS, et al. (2012) Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One, 7:e43726 doi: 10.1371/journal.pone.0043726.
15. Hermansen S, Dahlrot RH, Nielsen BS, Hansen S, Kristensen BW (2013) MiR-21 expression in the tumour cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol 111: 71-81.
16. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, et al. (2010) hsa-mir-210 is a marker of tumour hypoxia and a prognostic factor in head and neck cancer. Cancer 116: 2148-2158.
17. Chen Z, Li Y, Zhang H, Huang P, Luthra R (2010) Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 29: 4362-4368.
18. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, et al. (2009) MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8: 2756-2768.
19. Puisségur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, et al. (2011) miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 18: 465-478.
20. Fasanaro P, Greco S, Lorenzi M, Pescatori M, Brioschi M, et al. (2009) An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem 284: 35134-35143.
21. Fasanaro P, Romani S, Voellenkle C, Maimone B, Capogrossi MC, et al. (2012) ROD1 is a seedless target gene of hypoxia-induced miR-210. PLoS One 7:e44651.